These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 21710556

  • 1. Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients.
    Ajimura TO, Borges KB, Ferreira AF, de Castro FA, de Gaitani CM.
    Electrophoresis; 2011 Jul; 32(14):1885-92. PubMed ID: 21710556
    [Abstract] [Full Text] [Related]

  • 2. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, Haase D, Armbrust T, Cameron S, Ramadori G, Oellerich M, Walson P.
    Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
    Tsutsumi Y, Kanamori H, Yamato H, Ehira N, Miura T, Kawamura T, Obara S, Tanaka J, Asaka M, Imamura M, Masauzi N.
    Leuk Res; 2004 Oct; 28(10):1117-8. PubMed ID: 15289027
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS.
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [Abstract] [Full Text] [Related]

  • 12. A method for quantitative analysis of an anticancer drug in human plasma with CE-ESI-TOF-MS.
    Elhamili A, Bergquist J.
    Electrophoresis; 2011 Jun; 32(13):1778-85. PubMed ID: 21706500
    [Abstract] [Full Text] [Related]

  • 13. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1089-97. PubMed ID: 17317816
    [Abstract] [Full Text] [Related]

  • 19. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D'Incalci M.
    Clin Cancer Res; 2003 Feb 15; 9(2):625-32. PubMed ID: 12576428
    [Abstract] [Full Text] [Related]

  • 20. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res; 2006 Dec 15; 12(24):7374-9. PubMed ID: 17189410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.